Compass Therapeutics price target raised to $8 from $7 at Jefferies

Jefferies raised the firm’s price target on Compass Therapeutics (CMPX) to $8 from $7 and keeps a Buy rating on the shares. The firm, which says it is positive on the second-line Phase 2/3 data readout for CTX-009, now named tovecimig, in patients with biliary tract cancer that is expected in March, continues to expect an objective response rate in the 40% range and progression free and overall survival in the 9 to 12 months range.